These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23146362)

  • 41. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improving the detection of degradants and impurities in pharmaceutical drug products by applying mass spectral and chromatographic searching.
    Freed AL; Kale U; Ando H; Rossi DT; Kingsmill CA
    J Pharm Biomed Anal; 2004 Jun; 35(4):727-38. PubMed ID: 15193717
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulatory perspectives from Japan - comparability of biopharmaceuticals.
    Kawanishi T
    Biologicals; 2006 Mar; 34(1):65-8. PubMed ID: 16330220
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An overview of the analytical characterization of nanostructured drug delivery systems: towards green and sustainable pharmaceuticals: a review.
    Domingo C; Saurina J
    Anal Chim Acta; 2012 Sep; 744():8-22. PubMed ID: 22935368
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Guidelines and pharmacopoeial standards for pharmaceutical impurities: overview and critical assessment.
    Snodin DJ; McCrossen SD
    Regul Toxicol Pharmacol; 2012 Jul; 63(2):298-312. PubMed ID: 22507740
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validation of analytical methods involved in dissolution assays: acceptance limits and decision methodologies.
    Rozet E; Ziemons E; Marini RD; Boulanger B; Hubert P
    Anal Chim Acta; 2012 Nov; 751():44-51. PubMed ID: 23084050
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potential.
    Kraynov E; Martin SW; Hurst S; Fahmi OA; Dowty M; Cronenberger C; Loi CM; Kuang B; Fields O; Fountain S; Awwad M; Wang D
    Drug Metab Dispos; 2011 Oct; 39(10):1779-83. PubMed ID: 21768274
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mass spectrometry analysis of new chemical entities for pharmaceutical discovery.
    Fang AS; Miao X; Tidswell PW; Towle MH; Goetzinger WK; Kyranos JN
    Mass Spectrom Rev; 2008; 27(1):20-34. PubMed ID: 18033735
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Unraveling the dynamics of protein interactions with quantitative mass spectrometry.
    Ramisetty SR; Washburn MP
    Crit Rev Biochem Mol Biol; 2011 Jun; 46(3):216-28. PubMed ID: 21438726
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Strategies and methods in the identification of antagonists of protein-protein interactions.
    Gadek TR
    Biotechniques; 2003 Jun; Suppl():21-4. PubMed ID: 12813901
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients.
    Jorgensen L; Hostrup S; Moeller EH; Grohganz H
    Expert Opin Drug Deliv; 2009 Nov; 6(11):1219-30. PubMed ID: 19678792
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Methodology for the validation of analytical methods involved in uniformity of dosage units tests.
    Rozet E; Ziemons E; Marini RD; Boulanger B; Hubert P
    Anal Chim Acta; 2013 Jan; 760():46-52. PubMed ID: 23265732
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dosage form design and development.
    Allen LV
    Clin Ther; 2008 Nov; 30(11):2102-11. PubMed ID: 19108798
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Investigation of protein conformational stability employing a multimodal spectrometer.
    Hu L; Olsen C; Maddux N; Joshi SB; Volkin DB; Middaugh CR
    Anal Chem; 2011 Dec; 83(24):9399-405. PubMed ID: 22047496
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Editorial and Review: 28th ASMS Sanibel Conference on Mass Spectrometry-Characterization of Protein Therapeutics by Mass Spectrometry.
    Sperry JB; Chen G; Loo JA
    J Am Soc Mass Spectrom; 2017 May; 28(5):781-785. PubMed ID: 28374311
    [No Abstract]   [Full Text] [Related]  

  • 57. Microfluidic Approaches for the Characterization of Therapeutic Proteins.
    Kopp MRG; Arosio P
    J Pharm Sci; 2018 May; 107(5):1228-1236. PubMed ID: 29325925
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products.
    Carpenter JF; Randolph TW; Jiskoot W; Crommelin DJ; Middaugh CR; Winter G
    J Pharm Sci; 2010 May; 99(5):2200-8. PubMed ID: 19918982
    [No Abstract]   [Full Text] [Related]  

  • 59. In Vivo Stability of Therapeutic Proteins.
    Schuster J; Koulov A; Mahler HC; Detampel P; Huwyler J; Singh S; Mathaes R
    Pharm Res; 2020 Jan; 37(2):23. PubMed ID: 31900680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions.
    Chow AT; Earp JC; Gupta M; Hanley W; Hu C; Wang DD; Zajic S; Zhu M;
    J Clin Pharmacol; 2014 May; 54(5):593-601. PubMed ID: 24272952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.